Perspective Therapeutics (CATX) Common Equity (2016 - 2025)
Perspective Therapeutics (CATX) has disclosed Common Equity for 15 consecutive years, with $207.0 million as the latest value for Q4 2025.
- Quarterly Common Equity fell 28.77% to $207.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $207.0 million through Dec 2025, down 28.77% year-over-year, with the annual reading at $207.0 million for FY2025, 28.77% down from the prior year.
- Common Equity hit $207.0 million in Q4 2025 for Perspective Therapeutics, down from $242.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $341.0 million in Q2 2024 to a low of $54.6 million in Q4 2022.
- Historically, Common Equity has averaged $154.6 million across 5 years, with a median of $103.7 million in 2023.
- Biggest five-year swings in Common Equity: skyrocketed 1190.66% in 2021 and later decreased 28.77% in 2025.
- Year by year, Common Equity stood at $64.4 million in 2021, then decreased by 15.14% to $54.6 million in 2022, then skyrocketed by 37.58% to $75.2 million in 2023, then surged by 286.63% to $290.7 million in 2024, then fell by 28.77% to $207.0 million in 2025.
- Business Quant data shows Common Equity for CATX at $207.0 million in Q4 2025, $242.2 million in Q3 2025, and $265.7 million in Q2 2025.